AM833
The Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. In the United States, most of these compounds are not FDA-approved and are sold for laboratory research only; a few are prescription drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
An amylin analog from Novo Nordisk, studied both standalone (REDEFINE program) and paired with semaglutide as the combination product CagriSema (see that entry separately – CagriSema is further along in review). REDEFINE 1's standalone monotherapy arm showed roughly 10.8% mean weight loss at the 4.5 mg maintenance dose over 32 weeks; REDEFINE 2 mapped the dose-response curve from 0.3 to 4.5 mg.